• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of annrheumdAnnals of the Rheumatic DiseasesVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
Ann Rheum Dis. Jul 2006; 65(7): 970–971.
PMCID: PMC1798194

No change of serum levels of leptin and adiponectin during anti‐tumour necrosis factor antibody treatment with adalimumab in patients with rheumatoid arthritis

Leptin and adiponectin, two fat tissue hormones, are increased or tend to be increased in patients with rheumatoid arthritis (RA).1,2 They are likely to be stimulated by proinflammatory cytokines such as tumour necrosis factor (TNF),3,4 and both were found to be increased in the synovial fluid of patients with RA.1,2 Thus, one would expect lowering of serum levels of these two hormones during anti‐TNF antibody treatment.

As part of a recently published study with adalimumab (Abbott SpA, Campoverde di Aprilia, Italy),5 we included 32 white patients with RA (30 postmenopausal women, two men) fulfilling the American College of Rheumatology criteria for RA.6 The patients were selected according to the inclusion criteria of the adalimumab Research in Active RA study (ReAct). A total of 16 patients (15 female, one male) did not receive parallel or prior (6 months before) prednisolone treatment. The other 16 patients (15 female, one male) received prednisolone treatment (mean (SEM) 4.6 (0.2) mg/day). The initial mean (SEM) body mass index in the two groups was 22.8 (0.8) kg/m2 (without prednisolone) and 22.3 (0 8) kg/m2 (with prednisolone). We did not see any obvious change of body weight throughout the study. All patients were given additional methotrexate (stable throughout this study) but no other immunosuppressive drugs. Patients were assigned to receive single self‐injections of adalimumab subcutaneously at 40 mg every other week. A baseline blood sample was taken 1–2 weeks before the start of adalimumab treatment. Anti‐TNF antibodies were infused on weeks 0, 2, 4, 6, 8, 10, and 12. For this study, patients were clinically investigated and blood was drawn between 8 am and 9 am when the patients visited the outpatient clinic on the baseline day and at weeks 2, 6, and 12. The blood was immediately centrifuged and serum was stored at −80°C. The study was approved by the ethics committee of L Sacco University Hospital, Italy.

We used enzyme immunometric assays for the quantitative determination of serum levels of leptin (IBL, Hamburg, Germany), adiponectin (R&D Systems, Wiesbaden, Germany), and interleukin (IL)6 (R&D Systems). Intra‐assay and interassay coefficients of variation for all tests were <10%.

Table 11 shows that during 12 weeks of adalimumab treatment in patients, with and without prednisolone, typical measures of inflammation markedly decreased. This indicates that adalimumab was effective in reducing RA associated inflammation. However, serum levels of leptin and adiponectin did not change during adalimumab treatment (fig 11).). Interestingly, although having similar body mass indices, patients with prior prednisolone treatment had markedly decreased serum levels of adiponectin in comparison with patients without glucocorticoids (fig 11).). This difference remained constant throughout the observation period (fig 11).

Table thumbnail
Table 1 Course of response measures during 12 weeks of adalimumab treatment
figure ar40857.f1
Figure 1 Course of serum levels of leptin (A) and adiponectin (B) in patients with RA with (black symbols) and without (white symbols) prednisolone treatment. A comparison of the two groups in (B) was carried out using the general linear model ...

In this study, we expected a decrease of serum levels of leptin and adiponectin in patients with RA receiving adalimumab treatment because both hormones are thought to be stimulated by proinflammatory cytokines such as TNF.3,4 We do not believe that an increase of body fat mass has masked a leptin fall because not one anti‐TNF treatment study has reported a dramatic effect on body fat mass (even in inflammatory bowel diseases). In addition, others did not find a correlation between serum levels of leptin and disease activity in patients with RA and juvenile arthritis,7,8 which may demonstrate that in these patients the link between inflammation and serum levels of leptin is probably not strong. This finding was later confirmed by another group.9 Others have demonstrated that serum leptin levels are inversely correlated with markers of inflammation such as C reactive protein.10 In our study we did not find any correlation between serum levels of leptin or adiponectin and the number of swollen joints or tender joints, serum IL6, C reactive protein (data not shown, but p values are >0.2). However, adiponectin levels were lower in the patients with RA who had been treated with prednisone; the reason for this is presently unknown.

In conclusion, in patients with RA, serum levels of leptin and adiponectin are not linked to inflammation and are not down regulated by 12 weeks of anti‐TNF treatment.


This study was supported by the respective institutions and Abbott SpA., Campoverde di Aprilia, Italy.


Conflict of interest: None.


1. Bokarewa M, Bokarew D, Hultgren O, Tarkowski A. Leptin consumption in the inflamed joints of patients with rheumatoid arthritis. Ann Rheum Dis 2003. 62952–956.956 [PMC free article] [PubMed]
2. Schäffler A, Ehling A, Neumann E, Herfarth H, Tarner I, Schölmerich J. et al Adipocytokines in synovial fluid. JAMA 2003. 2901709–1710.1710 [PubMed]
3. Zumbach M S, Boehme M W, Wahl P, Stremmel W, Ziegler R, Nawroth P P. Tumor necrosis factor increases serum leptin levels in humans. J Clin Endocrinol Metab 1997. 824080–4082.4082 [PubMed]
4. Delaigle A M, Jonas J C, Bauche I B, Cornu O, Brichard S M. Induction of adiponectin in skeletal muscle by inflammatory cytokines: in vivo and in vitro studies. Endocrinology 2004. 1455589–5597.5597 [PubMed]
5. Straub R H, Sarzi‐Puttini P, Atzeni F, Buttgereit F, Carrabba M, Cutolo M. Anti‐tumour necrosis factor antibody treatment does not change serum levels of cortisol binding globulin in patients with rheumatoid arthritis but it increases androstenedione relative to cortisol. Ann Rheum Dis 2005. 641353–1356.1356 [PMC free article] [PubMed]
6. Arnett F C, Edworthy S M, Bloch D A, McShane D J, Fries J F, Cooper N S. et al The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988. 31315–324.324 [PubMed]
7. Anders H J, Rihl M, Heufelder A, Loch O, Schattenkirchner M. Leptin serum levels are not correlated with disease activity in patients with rheumatoid arthritis. Metabolism 1999. 48745–748.748 [PubMed]
8. Perfetto F, Tarquini R, Simonini G, Bindi G, Mancuso F, Guiducci S. et al Circulating leptin levels in juvenile idiopathic arthritis: a marker of nutritional status? Ann Rheum Dis 2005. 64149–152.152 [PMC free article] [PubMed]
9. Toussirot E, Nguyen N U, Dumoulin G, Aubin F, Cedoz J P, Wendling D. Relationship between growth hormone‐IGF‐I‐IGFBP‐3 axis and serum leptin levels with bone mass and body composition in patients with rheumatoid arthritis. Rheumatology (Oxford) 2005. 44120–125.125 [PubMed]
10. Popa C, Netea M G, Radstake T R, van Riel P L, Barrera P, van der Meer J W. Markers of inflammation are negatively correlated with serum leptin in rheumatoid arthritis. Ann Rheum Dis 2005. 641195–1198.1198 [PMC free article] [PubMed]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Group
PubReader format: click here to try


Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • PubMed
    PubMed citations for these articles
  • Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...